DOI: 10.1055/s-00000069

Seminars in Liver Disease

References


A phase III randomized, double-blind, placebo-controlled study of sorafenib as adjuvant treatment for hepatocellular carcinoma after surgical resection or local ablation.
Available at:
http://clinicaltrials.gov/ct2/show/NCT00692770 . Accessed February 23, 2012

Download Bibliographical Data

Search in: